Your current location:Home > News > Industry News

Novo Nordisk Shanghai and Shanghai Pharmaceutical Holding will make another breakthrough in signing

Time:2022-12-09 16:41:18  Source:  Author:


 At the Fifth China International Import Expo, Novo Nordisk (Shanghai) Pharmaceutical Trade Co., Ltd. (hereinafter referred to as "Novo Nordisk Shanghai") and Shanghai Pharmaceutical Holding Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceutical Holding") held a strategic cooperation contract.

Shanghai Pharmaceutical Holding will provide Novo Nordisk Shanghai with an intelligent modern logistics warehouse through innovative pharmaceutical third-party logistics services, and further meet the future business development needs of Novo Nordisk Shanghai and help Novo Nordisk better serve Chinese patients with intensive, standardized, information-based and intelligent drug logistics management and operations.

Zhang Qing, Deputy Director of Shanghai Municipal Food and Drug Administration, said that this cooperation is full of innovation, foresight and demonstration. It is a beneficial exploration for Shanghai Pharmaceutical Holding to participate in the global medical industry with industry partners and integrate into the international and domestic double cycle. It is also an important measure to help Shanghai further play its leading role in the biomedical industry and accelerate the construction of an innovation highland of the biomedical industry with international influence.

Zhang Qing hopes that Shanghai Pharmaceutical Holding and Novo Nordisk will build the cooperation project into a shining business card of the new area near the port and contribute to promoting a new round of high-quality development of Shanghai's biomedical industry.

Li Yongzhong, Executive Director and Vice President of Shanghai Pharmaceutical and General Manager of Shanghai Pharmaceutical Holding, said that in the past 20 years, Shanghai Pharmaceutical Holding has participated in many blockbuster products of Novo Nordisk. These efforts have led to the steady growth of bilateral cooperation. The signing of this strategic cooperation will be an innovative breakthrough in the pharmaceutical tripartite logistics between the two sides.

Zhou Xiaping, senior vice president of Novo Nordisk and president of Greater China, said: "This investment and construction is an important step for Novo Nordisk to achieve a new layout of the whole industrial chain of" two centers, three engines ", which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients." "Two centers and three engines" means that Novo Nordisk's Greater China Trade and Innovation Center is located in Shanghai, the Greater China Production Center is located in Tianjin, and the R&D engine in China is located in Beijing.

Since entering China in 1994, Novo Nordisk has established a full industrial chain layout integrating R&D, production and operation. In the five years since its participation in the Expo, Novo Nordisk has invested in China five times, with a total investment of more than 2.5 billion yuan.

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL:+86-21-33585366(DDT)、34666753 FAX:+86-21-34979012
E-mail:info@shyrchem.com ADD:1885 Metropolitan Road, Minhang District, Shanghai Code:201108